Company news
Mirum Pharmaceuticals, Inc. news in 2021
Mirum Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
December 14, 2021
LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021
December 12, 2021
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
December 5, 2021
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
November 16, 2021
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
November 14, 2021
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 14, 2021
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
November 7, 2021
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
October 31, 2021
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
October 31, 2021
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
September 28, 2021
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
September 20, 2021
Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
September 12, 2021
Mirum Pharmaceuticals to Participate in September Investor Conferences
September 1, 2021
Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
August 18, 2021
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 4, 2021
Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea
July 25, 2021
Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
June 6, 2021
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 5, 2021
Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
April 28, 2021
Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome
April 25, 2021
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
April 11, 2021
Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome
March 28, 2021
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates
March 8, 2021
Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome
January 31, 2021
Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign
January 23, 2021
Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis
January 13, 2021
Mirum Pharmaceuticals Provides Corporate Update
January 11, 2021
Calls in 2021
Decks in 2021
- Technical Presentation (September 2021)
Technical · 18 slides · Sep 21, 2021